Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke(Moffitt Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Brian T. Hill(Cleveland Clinic), Patrick J. Stiff(Loyola University Medical Center), Jaeyeon Kim(Sidney Kimmel Cancer Center), Ira Braunschweig(The University of Texas MD Anderson Cancer Center), Alex F. Herrera(City of Hope), Yizhou Jiang(University of Pennsylvania), Caron A. Jacobson(Dana-Farber Cancer Institute), Jeffrey S. Wiezorek(Kite (United States)), Olalekan O. Oluwole(Vanderbilt University), Allen Xue(Amgen (United States)), Lynn Navale(Moffitt Cancer Center), Abhinav Deol(Wayne State University), Adrian Bot(Unknown), John M. Timmerman(Sheba Medical Center), Lazaros J. Lekakis(University of Miami Hospital), Nancy L. Bartlett(Washington University in St. Louis), Patrick M. Reagan(University of Rochester), David B. Miklos(Stanford University), Julio C. Chávez(Moffitt Cancer Center), Armin Ghobadi(Washington University in St. Louis), André Goy(Hackensack University Medical Center), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Yi Lin, Umar Farooq(Wake Forest University), Peter A. McSweeney(Mesoblast (United States)), William Y. Go(Amgen (United States)), Ian W. Flinn(Tennessee Oncology), John M. Rossi(Amgen (United States)), Tanya Siddiqi(City Of Hope National Medical Center)

The Lancet Oncology

December 2, 2018

Cited by 2,283

|New England Journal of Medicine|2017|6k

|Science Translational Medicine|2014|5.1k

|Transplantation and Cellular Therapy|2018|3.6k

|New England Journal of Medicine|2018|2.3k

|New England Journal of Medicine|2013|2.2k

Related Papers